Moderne Diagnosestellung der Amyotrophen Lateralsklerose – ein Update der Diagnosekriterien

Die Diagnose der Amyotrophen Lateralsklerose ist weiterhin eine Herausforderung. Sowohl die revidierten El-Escorial-Kriterien als auch die Awaji-Kriterien werden zum Teil in der klinischen Praxis genutzt, sind jedoch komplex und wenig sensitiv. Die neu vorgeschlagenen Gold-Coast-Kriterien stellen eine Erleichterung im klinischen Alltag dar. Eine Veranschaulichung der Diagnosefindung nach den verschiedenen Kriterien findet sich in dem Fallbeispiel.

The diagnosis of amyotrophic lateral sclerosis (ALS) is still challenging for clinicians. In the absence of a reliable biomarker, the clinical and electromyographic examination is of major importance to diagnose ALS. Mainly developed for clinical trials, the well-established revised El-Escorial criteria and Awaji criteria are sometimes also used in clinical routine. However, both diagnostic criteria are complex and disconcerting especially for patients because of various categories like “possible ALS” and “probable ALS”. Additionally, a definite diagnosis can only be made late in the course of the disease, or even sometimes it is not possible to fulfill the diagnostic criteria. The newly proposed Gold Coast criteria are a simplified synopsis of the previous diagnostic criteria. The combination of progressive symptoms, clinical or electromyographic evidence of lower and upper motor neuron dysfunction or progressive lower motor neuron dysfunction, and the exclusion of other diseases lead to the diagnosis of ALS.

Schlüsselwörter

Amyotrophe Lateralsklerose - El-Escorial-Kriterien - Awaji-Kriterien - Gold-Coast-Kriterien

Key word

amyotrophic lateral sclerosis - El Escorial criteria - Awaji criteria - Gold Coast Criteria

Publication History

Article published online:
02 March 2022

• Literatur

• 1 Goetz CG. Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot. Muscle Nerve 2000; 23: 336-343 DOI: 10.1002/(sici)1097-4598(200003)23:3<336::aid-mus4>3.0.co;2-l.
• 2 Chio A, Moglia C, Canosa A. et al. Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology 2019; 93: e984-e994 DOI: 10.1212/WNL.0000000000008063.
• 3 Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci 2013; 14: 248-264 DOI: 10.1038/nrn3430.
• 4 Chio A, Logroscino G, Traynor BJ. et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 2013; 41: 118-130 DOI: 10.1159/000351153.
• 5 Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci 2001; 191: 3-9 DOI: 10.1016/s0022-510x(01)00630-x.
• 6 McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend Med 2010; 7: 557-570 DOI: 10.1016/j.genm.2010.11.010.
• 7 Mulder DW, Kurland LT, Offord KP. et al. Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology 1986; 36: 511-517 DOI: 10.1212/wnl.36.4.511.
• 8 Chio A, Traynor BJ, Lombardo F. et al. Prevalence of SOD1 mutations in the Italian ALS population. Neurology 2008; 70: 533-537 DOI: 10.1212/01.wnl.0000299187.90432.3f.
• 9 Henderson RD, Daube JR. Decrement in surface-recorded motor unit potentials in amyotrophic lateral sclerosis. Neurology 2004; 63: 1670-1674 DOI: 10.1212/01.wnl.0000142534.78461.42.
• 10 Feinberg DM, Preston DC, Shefner JM. et al. Amplitude-dependent slowing of conduction in amyotrophic lateral sclerosis and polyneuropathy. Muscle Nerve 1999; 22: 937-940 DOI: 10.1002/(sici)1097-4598(199907)22:7<937::aid-mus19>3.0.co;2-6.
• 11 Ludolph A, Petri S, Grosskreutz J. et al. Motoneuronerkrankungen, S1-Leitlinie, 2021. In: Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie https://dgn.org/leitlinien/ll-030-001-motoneuronerkrankungen-2021/ Stand: 01.01.2022
• 12 Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – First Revision. J Peripher Nerv Syst 2010; 15: 1-9 DOI: 10.1111/j.1529-8027.2010.00245.x.
• 13 Daube JR. Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders. Muscle Nerve 2000; 23: 1488-1502 DOI: 10.1002/1097-4598(200010)23:10<1488::aid-mus4>3.0.co;2-e.
• 14 Triggs WJ, Menkes D, Onorato J. et al. Transcranial magnetic stimulation identifies upper motor neuron involvement in motor neuron disease. Neurology 1999; 53: 605-611 DOI: 10.1212/wnl.53.3.605.
• 15 Reijn TS, Abdo WF, Schelhaas HJ. et al. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol 2009; 256: 615-619 DOI: 10.1007/s00415-009-0131-z.
• 16 Steinacker P, Feneberg E, Weishaupt J. et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 2016; 87: 12-20 DOI: 10.1136/jnnp-2015-311387.
• 17 Verde F, Steinacker P, Weishaupt JH. et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2019; 90: 157-164 DOI: 10.1136/jnnp-2018-318704.
• 18 Khalil M, Teunissen CE, Otto M. et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018; 14: 577-589 DOI: 10.1038/s41582-018-0058-z.
• 19 Misawa S, Noto Y, Shibuya K. et al. Ultrasonographic detection of fasciculations markedly increases diagnostic sensitivity of ALS. Neurology 2011; 77: 1532-1537 DOI: 10.1212/WNL.0b013e318233b36a.
• 20 Cartwright MS, Walker FO, Griffin LP. et al. Peripheral nerve and muscle ultrasound in amyotrophic lateral sclerosis. Muscle Nerve 2011; 44: 346-351 DOI: 10.1002/mus.22035.
• 21 Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 1994; 124: 96-107 DOI: 10.1016/0022-510x(94)90191-0.
• 22 Brooks BR, Miller RG, Swash M. et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293-299 DOI: 10.1080/146608200300079536.
• 23 de Carvalho M, Dengler R, Eisen A. et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008; 119: 497-503 DOI: 10.1016/j.clinph.2007.09.143.
• 24 Costa J, Swash M, de Carvalho M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis:a systematic review. Arch Neurol 2012; 69: 1410-1416 DOI: 10.1001/archneurol.2012.254.
• 25 Ido BJF, Kacem I, Ouedraogo M. et al. Sensitivity of Awaji Criteria and Revised El Escorial Criteria in the Diagnosis of Amyotrophic Lateral Sclerosis (ALS) at First Visit in a Tunisian Cohort. Neurol Res Int 2021; 2021: 8841281 DOI: 10.1155/2021/8841281.
• 26 Traynor BJ, Codd MB, Corr B. et al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch Neurol 2000; 57: 1171-1176 DOI: 10.1001/archneur.57.8.1171.
• 27 Shefner JM, Al-Chalabi A, Baker MR. et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol 2020; 131: 1975-1978 DOI: 10.1016/j.clinph.2020.04.005.
• 28 Hannaford A, Pavey N, van den Bos M. et al. Diagnostic Utility of Gold Coast Criteria in Amyotrophic Lateral Sclerosis. Ann Neurol 2021; 89: 979-986 DOI: 10.1002/ana.26045.
• 29 Pugdahl K, Camdessanche JP, Cengiz B. et al. Gold Coast diagnostic criteria increase sensitivity in amyotrophic lateral sclerosis. Clin Neurophysiol 2021; 132: 3183-3189 DOI: 10.1016/j.clinph.2021.08.014.